BRAF and colorectal carcinoma: There was no difference in the survival rate of CRC patients carrying BRAFV600E mutation with MSI-H when compared to those with unmutated BRAF; however, BRAFV600E mutated CRC with MSS was highly malignant and lack of effective treatment, resulting in a very poor prognosis [3, 4].